1. Follath F, Yilmaz MB, Delgado JF et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 2011; 37: 619–626.
2. Siirilä-Waris K, Lassus J, Melin J et al. FINN--AKVA Study Group. Characteristics, Outcomes, and Predictors of 1-year Mortality in Patients Hospitalized for Acute Heart Failure. Eur Heart J 2006; 27: 3011–3017.
3. Nieminen M, Brutsaert D, Dickstein K et al. EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a Survey on Hospitalized Acute Heart Failure Patients: Description of Population. Eur Heart J 2006; 27: 2725–2736.
4. Cleland J, Swedberg K, Follath F et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey Programme – a Survey on the Quality of Care Among Patients with Heart Failure in Europe. Part 1: Patient Characteristics and Diagnosis. Eur Heart J 2003; 24: 442–463.
5. Fonarow GC, Abraham WT, Albert NM et al. Influence of a Performance-improvement Initiative on Quality of Care for Patients Hospitalized with Heart Failure: Results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 2007; 167: 1493–1502.
6. Spinar J, Parenica J, Vitovec J et al. Baseline Characteristics and Hospital Mortality in the Acute Heart Failure Database (AHEAD) Main Registry. Crit Care 2011; 15: R291.
7. Parenica J, Spinar J, Vitovec J et al. Long-term Survival Following Acute Heart Failure: The Acute Heart Failure Database Main Registry (AHEAD Main). Eur J Internal Med [Epub ahead of print].
8. Forman DE, Butler J, Wang Y et al. Incidence, Predictors at Admission, and Impact of Worsening Renal Function Among Patients Hospitalized with Heart Failure. J Am Coll Cardiol 2004; 43: 61–67.
9. Cowie M, Komajda M, Murray-Thomas T et al. POSH Investigators. Prevalence and Impact of Worsening Renal Function in Patients Hospitalized with Decompensated Heart Failure: Results of the Prospective Outcomes Study in Heart Failure (POSH). Eur Heart J 2006; 27: 1216–1222.
10. Metra M, Nodari S, Parrinello G et al. Worsening Renal Function in Patients Hospitalised for Acute Heart Failure: Clinical Implications and Prognostic Significance. Eur J Heart Fail 2008; 10: 188–195.
11. Tomcikova D, Felsoci M, Spinar J et al. Risk of In-hospital Mortality Identified According to the Typology of Patients with Acute Heart Failure: Classification Tree Analysis on Data from the Acute Heart Failure Database-Main Registry. J Crit Care 2012, doi: 10.1016/j.jcrc.2012.09.014. [Epub ahead of print].
12. Aronson D, Burger A. The Relationship Between Transient and Persistent Worsening Renal Function and Mortality in Patients with Acute Decompensated Heart Failure. J Card Fail 2010; 16: 541–547.
13. Heywood JT, Fonarow GC, Costanzo MR et al. High Prevalence Of Renal Dysfunction And Its Impact On Outcome In 118,465 Patients Hospitalized With Acute Decompensated Heart Failure: A Report From The ADHERE Database. J Card Fail 2007; 13: 422–430.
14. Ronco C, McCullough P, Anker S et al. Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio--renal Syndromes: Report from the Consensus Conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010; 31: 703–711.
15. Ronco C, House AA, Haapio M et al. Cardiorenal Syndrome: Refining the Definition of a Complex Symbiosis Gone Wrong. Intensive Care Med 2008; 34: 957–962.
16. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and Classification of Chronic Kidney Disease: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–2100.
17. Lombardi R, Nin N, Lorente JA et al. An assessment of the Acute Kidney Injury Network creatinine-based criteria in patients submitted to mechanical ventilation. Clin J Am Soc Nephrol 2011; 6: 1547–1555.
18. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: Report of an Initiative to Improve Outcomes in Acute Kidney Injury. Crit Care 2007; 11: R31.
19. Ismail Y, Kasmikha Z, Green H et al. Cardio-renal Syndrome Type 1: Epidemiology, Pathophysiology, and Treatment. Semin Nephrol 2012; 32: 18–25.
20. Breidthardt T, Socrates T, Drexler B et al. Plasma Neutrophil Gelatinase-associated Lipocalin for the Prediction of Acute Kidney Injury in Acute Heart Failure. Crit Care 2012; 16: R2.
21. Werdan K, Ruß M, Buerke M et al. German Cardiac Society; German Society of Intensive Care and Emergency Medicine; German Society for Thoracic and Cardiovascular Surgery; (Austrian Society of Internal and General Intensive Care Medicine; German Interdisciplinary Association of Intensive Care and Emergency Medicine; Austrian Society of Cardiology; German Society of Anaesthesiology and Intensive Care Medicine; German Society of Preventive Medicine and Rehabilitation. Cardiogenic Shock Due to Myocardial Infarction: Diagnosis, Monitoring and Treatment: a German-Austrian S3 Guideline. Dtsch Arztebl Int. 2012; 109: 343–351.
22. Pannu N, Manns B, Lee H et al. Systematic Review of the Impact of N-acetylcysteine on Contrast Nephropathy. Kidney Int 2004; 65: 1366–1374.
23. Mullens W, Abrahams Z, Francis G et al. Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure. J Am Coll Cardiol 2009; 53: 589–596.
24. McMurray J, Adamopoulos S, Anker S et al. ESC Committee for Practice Guidelines. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in Collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803–869.
25. Butler J, Forman D, Abraham W et al. Relationship Between Heart Failure Treatment and Development of Worsening Renal Function Among Hospitalized Patients. Am Heart J 2004; 147: 331–338.
26. Felker GM, Lee KL, Bull DA et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. N Engl J Med 2011; 364: 797–805.
27. Lindenfeld J, Albert N, Boehmer J et al. Heart Failure Society of America, Lindenfeld J. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16: e1–e194.
28. Channer K, McLean K, Lawson-Matthew P et al. Combination Diuretic Treatment in Severe Heart Failure: a Randomised Controlled Trial. Br Heart J 1994; 71: 146–150.
29. Dormans TP, Gerlag PG. Combination of High--dose Furosemide and Hydrochlorothiazide in the Treatment of Refractory Congestive Heart Failure. Eur Heart J 1996; 17: 1867–1874.
30. Amer M, Adomaityte J, Qayyum R. Continuous Infusion Versus Intermittent Bolus Furosemide in ADHF: An Updated Meta-analysis of Randomized Control Trials. J Hosp Med 2012; 7: 270–275.
31. Hawkins E, Malesker M, Hilleman D et al. A Retrospective Analysis of Intermittent Bolus Dosing Versus Continuous Infusion Dosing of Furosemide in Critical Care Patients With Diuretic Resistance. CHEST 2012; 142: 402A–402A.
32. Parrinello G, Di Pasquale P, Torres D et al. Troponin I Release After Intravenous Treatment with High Furosemide Doses Plus Hypertonic Saline Solution in Decompensated Heart Failure Trial (Tra-HSS-Fur). Am Heart J 2012; 164: 351–357.
33. Licata G, Di Pasquale P, Parrinello G et al. Effects of High-dose Furosemide and Small-volume Hypertonic Saline Solution Infusion in Comparison with a High Dose of Furosemide as Bolus in Refractory Congestive Heart Failure: Long-term Effects. Am Heart J 2003; 145: 459–466.
34. Pitt B, Zannad F, Remme J et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717.
35. Zannad F, McMurray JJV, Krum H et al. EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364: 11–21.
36. McMurray J, Adamopoulos S, Anker S et al. ESC Committee for Practice Guidelines. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in Collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–1847.
37. Zannad F, Gattis Stough W, Rossignol P et al. Mineralocorticoid Receptor Antagonists for Heart Failure with Reduced Ejection Fraction: Integrating Evidence into Clinical Practice. Eur Heart J 2012; 33: 2782–2795.
38. Ceremuzyński L, Budaj A, Michorowski A et al. Single-dose i.v. Aldactone for Congestive Heart Failure: a Preliminary Observation. Int J Clin Pharmacol Ther Toxicol 1983; 21: 417–421.
39. Testani J, Kimmel S, Dries D et al. Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-converting Enzyme Inhibitor Therapy in Patients with Cardiac Dysfunction. Circ Heart Fail 2011; 4: 685–691.
40. Kellum JA, Decker J. Use of Dopamine in Acute Renal Failure: a Meta-analysis. Crit Care Med 2001; 29: 1526–1531.
41. Friedrich J, Adhikari N, Herridge MS et al. Meta--analysis: Low-dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or Death. Ann Intern Med 2005; 142: 510–524.
42. Giamouzis G, Butler J, Starling R et al. Impact of Dopamine Infusion on Renal Function in Hospitalized Heart Failure Patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 2010; 16: 922–930.
43. Miklik R, Parenica J, Felsoci M et al. Levosimendan v léčbě akutního srdečního selhání – zkušenosti z kardiologické kliniky. Cor Vasa 2009; 51: 507–512.
44. Yilmaz M, Yalta K, Yontar C et al. Levosimendan Improves Renal Function in Patients with Acute Decompensated Heart Failure: Comparison with Dobutamine. Cardiovasc Drugs Ther 2007; 21: 431–435.
45. Abraham WT, Adams KF, Fonarow GC et al. ADHERE Scientific Advisory Committee and Investigators, ADHERE Study Group. In-hospital Mortality in Patients with Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications: An Analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57–64.
46. Klein L, Massie B, Leimberger J et al. OPTIME--CHF Investigators. Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008; 1: 25–33.
47. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial. JAMA 2007; 297: 1319–1331.
48. Gheorghiade M, Gattis W, O‘Connor C et al. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: a Randomized Controlled Trial. JAMA 2004; 291: 1963–1971.
49. Bart B, Goldsmith S, Lee K et al. Heart Failure Clinical Research Network. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. N Engl J Med 2012 [Epub ahead of print].
50. Lewington A, Kanagasundaram S. Clinical Practice Guidelines for Acute Kidney Injury. 2010. www.renal.org/guidelines.